BiotechTube
BUHLMANN Diagnostics

BUHLMANN Diagnostics

Portland, United States· Est.
buhlmannlabs.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

BUHLMANN Diagnostics Corp is a U.S.-based provider of specialized diagnostic assays, serving as the commercial arm for the Swiss parent company BÜHLMANN Laboratories AG. The company has established a strong niche in gastrointestinal diagnostics, particularly with its BÜHLMANN fCAL® calprotectin assays, which are a gold standard for monitoring IBD. Its portfolio extends into allergy testing, neuroimmunology, and therapeutic drug monitoring, supported by proprietary technologies like the Quantum Blue® point-of-care platform and CALEX® Cap sample extraction system. As a private company, it leverages its parent's long-term R&D and manufacturing expertise to serve clinical and research laboratories in North America.

Gastroenterology (IBD)AutoimmunityAllergyNeuroimmunologyClinical Chemistry

Technology Platform

Proprietary immunoassays (ELISA, turbidimetric), Quantum Blue® point-of-care reader, CALEX® Cap sample extraction, IBDoc® remote monitoring system.

Opportunities

Growth in the fecal calprotectin testing market driven by IBD prevalence and guidelines favoring non-invasive monitoring.
Expansion into therapeutic drug monitoring for biologics aligns with the trend towards personalized medicine.
Strategic partnerships with large distributors can significantly expand commercial reach.

Risk Factors

Revenue concentration in the calprotectin product line creates vulnerability to competition or guideline changes.
The U.S.
subsidiary is dependent on the Swiss parent for R&D and manufacturing, posing supply chain and strategic control risks.
Reimbursement challenges for niche diagnostic tests in the U.S.
market could limit adoption.

Competitive Landscape

Competes in niche segments against specialized players like Eurospital (calprotectin), Thermo Fisher, and Werfen. Faces potential competition from large IVD conglomerates (Abbott, Roche, DiaSorin) who could enter its specialty markets. Its deep focus and proprietary technologies (CALEX® Cap, Quantum Blue®) provide competitive differentiation.

More companies in Diagnostics & Precision Medicine →More companies in United States →